短程同步放疗联合替莫唑胺对胶质母细胞瘤患者生存情况的影响

Abstract
Figure/Table
References (20)
Related Citation (12)

Download: PDF (688 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the influence of short term concurrent chemoradiotherapy combined with Temozolomide on the survival situations of patients with glioblastoma. Methods Sixty-five patients with glioblastoma receiving surgery treatment in the Affiliated Bayi Brain Hospital of Army General Hospital from June 2011 to June 2015 were selected as the research objects. According to the different treatments, the patients were divided into short term concurrent radiotherapy combined with Temozolomide group (combined group, 23 cases), short term concurrent radiation group (21 cases) and Temozolomide group (21 cases). The short term efficacy, progression free survival (PFS), overall survival (OS) and adverse reactions of the three groups were observed. In addition, the survival curves of the three groups were drawn. Results After treatment, the objective remission rate (ORR) in the combined group (56.52%) was significantly higher than that of short term concurrent radiation group (19.05%) and Temozolomide group (21.81%) (P ＜ 0.05). There was no statistically significant difference of ORR between short term concurrent radiation group and Temozolomide group (P ＞ 0.05). There was no statistically significant difference of the disease control rate (DCR) among the three groups (P ＞ 0.05). There was statistically significant difference of the median PFS among the three groups (P ＞ 0.05). There was no statistically significant difference of the median OS among the three groups (P ＜ 0.05). The rate of adverse reactions among the three groups had no significant difference(P ＞ 0.05). Conclusion Short term concurrent radiation combined with Temozolomide can improve the postoperative remission rate of patients with glioblastoma and prolong the survival period.

Key words： Glioblastoma Concurrent radiotherapy Temozolomide Survival benefit Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Jinbao LI Wende YU Bin LI Yunjun CHEN Lihua▲

Cite this article:

GAO Jinbao LI Wende YU Bin LI Yunjun CHEN Lihua▲. Influence of short term concurrent chemoradiotherapy combined with Temozolomide on the survival situations of patients with glioblastoma[J]. 中国医药导报, 2018, 15(17): 102-105.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I17/102

[1] 潘振宇，许海洋，于洪泉，等.卡铂联合替莫唑胺剂量密度方案治疗复发性胶质母细胞瘤的临床观察[J].中华神经外科杂志，2016，32（1）：38-42.
[2] 王政，姜炜，庞青松，等.胶质母细胞瘤同期推量 IMRT 安全性分析[J].中华放射肿瘤学杂志，2015，24（4）：431-433.
[3] 夏太玉，任庆兰.免疫治疗联合放化疗治疗胶质母细胞瘤的研究进展[J].现代肿瘤医学，2016，24（4）：650-653.
[4] 李壮玲，李先明，钟鹤立，等.胶质母细胞瘤术后IMRT和VMAT的剂量学比较[J].广东医学，2017，38（10）：1538-1541.
[5] 梁朝峰，湛浩强，骆众星，等.磁共振波谱成像对胶质母细胞瘤患者早期预后的预测意义[J].中华神经医学杂志，2017，16（11）：38-40.
[6] 张会.探索18F-RGD PET/CT对新诊断胶质母细胞瘤同步放化疗敏感性的预测价值[D].济南：济南大学，2016.
[7] Laufer M，Chan T，Yamada J，et al. Abbreviated Course of Radiation Therapy with Concurrent Temozolomide for High-grade Glioma in Patients of Advanced Age or Poor Functional Status [J]. J Neurooncol，2012，110（3）：369-374.
[8] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断和治疗指南（2012）[J].中华医学杂志，2013，93（31）：2418-2449.
[9] 杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，11（2）：85-90.
[10] Kaba H，Fukuda H，Yamamoto S，et al. Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0 [J]. Gan to Kagaku Ryoho，2004，31（8）：1187-1192.
[11] 张溢华，王昊，曾实，等.36例复发胶质母细胞瘤在治疗患者临床资料分析[J].重庆医学，2018，4（3）：365-367.
[12] 丁德智，侯现增，刘广存.复发性胶质母细胞瘤的研究进展[J].新医学，2016，47（12）：797-802.
[13] Malmstr?觟m A，Gr?覬nberg BH，Marosi C，et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma： the Nordic randomised， phase 3 trial [J]. Lancet Oncology，2012，13（9）：916-926.
[14] Fuller CD，Forthuber B，Rajagiriyil N，et al. 87 oral Intensity modulated radiation therapy （IMRT） in the treatment of primary glioblastoma multiforme： retrospective survival analysis[J]. Radiotherapy & Oncology，2004，73（1）：S39.
[15] Iwamoto FM，Cooper AR，Reiner AS，et al. Glioblastoma multiforme in the elderly： the Memorial Sloan-Kettering Cancer Center Experience（1997-2007）[J]. Cancer，2009， 115（16）：3758-3766.
[16] 孙德超，张智峰，魏震，等.贝伐单抗治疗胶质母细胞瘤相关标志物的研究进展[J].河南医学研究，2018，27（7）：1222-1224.
[17] 康恩铭，章薇，章翔.甲基化状态风险分析对胶质母细胞瘤患者预后评价意义[J].中华神经外科疾病研究杂志，2018，17（1）：27-31.
[18] 孙翠云，于士柱.腺样型胶质母细胞瘤[J].中国现代神经疾病杂志，2018，18（2）：117-122.
[19] 付朋，岑泳村，黄琴，等.VEGF受体3在人脑胶质母细胞瘤中的表达及作用[J].中华神经外科疾病研究杂志，2018，17（1）：4-8.
[20] 王娇燕，孟凡华，刘魏然.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志，2018， 23（1）：13-16.